Β -glucan combined with pd-1/pd-l1 checkpoint blockade for immunotherapy in patients with advanced cancer

HIGHLIGHTS

• who: Experimental Pharmacology et al. from the Department of Oncology, The Affiliated Hospital of Nanjing Medical University, No, People`s Hospital, China, Department of Oncology, Graduate School of Dalian Medical University, Dalian, China have published the article: u03b2 -Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer, in the Journal: (JOURNAL) of 15/Dec/2021
• how: The authors presented an experimental model to determine the therapeutic efficacy of oral WGP u03b2-glucan combined with PD-1/PD-L1-blocking antibodies in lung cancer mouse. Were analyzed using FlowJo . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.